Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
The company was incorporated in 2012 and is headquartered in San Carlos, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.26 Increased by +62.99% | -0.18 Decreased by -46.00% |
| Nov 11, 24 | -0.21 Increased by +59.62% | -0.25 Increased by +16.00% |
| Aug 7, 24 | -0.30 Increased by +26.83% | -0.33 Increased by +9.09% |
| May 9, 24 | -0.81 Decreased by -65.31% | -0.47 Decreased by -72.34% |
| Mar 14, 24 | -0.71 Decreased by -42.00% | -0.47 Decreased by -51.06% |
| Nov 13, 23 | -0.52 Increased by +1.89% | -0.45 Decreased by -15.56% |
| Aug 9, 23 | -0.41 Increased by +54.44% | -0.48 Increased by +14.58% |
| May 9, 23 | -0.49 Increased by +86.39% | -0.49 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | N/A Decreased by N/A% | 376.00 K Increased by +100.53% | - - |
| Dec 31, 24 | 0.00 Decreased by -100.00% | 376.00 K Increased by +100.60% | Increased by +N/A% Increased by +N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -18.37 M Increased by +59.73% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -26.68 M Increased by +24.04% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -71.15 M Decreased by -67.78% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 10.76 M Increased by +N/A% | -62.55 M Decreased by -57.31% | Decreased by -581.55% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -45.63 M Decreased by -50.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -35.12 M Increased by +28.46% | Decreased by N/A% Decreased by N/A% |